Date:2/4/2010

(unaudited) Three months ended Twelve months ended December 31, December 31, ------------ ------------ % % 2009 2008 Growth 2009 2008 Growth ---- ---- ------ ---- ---- ------ EPS as reported, diluted $2.01 $1.84 9% $5.03 $5.79 -13% Restructuring charges, net of tax 0.06 (a) 0.14 (a) 0.67 (a) 0.14 (a) Debt extinguishment and financing costs, net of tax - - 0.04 (b) - Purchased intangible amortization, net of tax 0.02 (c) 0.02 (c) 0.08 (c) 0.08 (c) Discrete tax items - - (0.24)(d) (0.17)(e) --- --- ----- ----- Adjusted EPS, diluted $2.09 $2.00 5% $5.58 $5.84 -4% ===== ===== ===== ===== Notes: (a) Represents the EPS impact of restructuring charges of $3.0 million ($2.2 million after tax) and 31.4 million ($23.0 million after tax) for the three months and twelve months ended December 31, 2009, respectively and $6.4 million ($4.7 million after tax) for the three and twelve months ended December 31, 2008, which primarily include severance and lease termination costs. (b) Represents the EPS impact of costs to tender $75 million of the Company's 4.85% $150 million Senior Notes and other financing-related costs totaling $1.8 million ($1.3 million after tax) for the twelve months ended December 31, 2009. (c) Represents the EPS impact of
'/>"/>

SOURCE Mettler-Toledo International Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine technology :

1. Mettler-Toledo International Inc. Reports Third Quarter 2009 Results
2. Mettler-Toledo International Inc. Announces Webcast of Presentation at Baird Industrial Conference
3. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
4. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
8. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
9. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
11. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers